Comparison of protein concentrations in serum versus plasma from Alzheimer’s patients
Comparison of protein concentrations in serum versus plasma from Alzheimer’s patients作者机构:Center for Neuroscience and Regenerative Medicine Uniformed Services University of the Health Sciences Bethesda USA Department of Academic and Institutional Resources and Technology University of North Texas Health Science Center Fort Worth USA Department of Clinical Sciences University of Texas Southwestern Medical Center Dallas USA Department of Internal Medicine University of North Texas Health Science Center Fort Worth USA Departments of Genetics and Neurology The Carolina Center for Genome Sciences and the Bowles Center for Alcohol Studies University of North Carolina Chapel Hill USA Institute for Aging and Alzheimer’s Disease Research University of North Texas Health Science Center Fort Worth USA
出 版 物:《Advances in Alzheimer's Disease》 (阿尔茨海默氏病研究进展(英文))
年 卷 期:2012年第1卷第3期
页 面:51-58页
学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题:Alzheimer’s Disease Serum Proteins Plasma Proteins
摘 要:Background: There is great interest in developing blood-based biomarkers for Alzheimer’s disease (AD);however, there is no consensus as to what blood fraction is most appropriate for analyzing particular markers. The current study provides empirical evidence regarding how blood-based proteins vary depending on whether they are assayed in serum or plasma. Methods: Weanalyzed concentrations of 100 proteins in matched samples of serum and plasma from 39 Caucasian AD participants from the Texas Alzheimer’s Research and Care Consortium bymultiplex immunoassay. Results: Concentrations of 40 proteins were highly correlated (r2≥ 0.75) between plasma and serum while the remaining proteins were moderately to weakly correlated (r2 0.75). Discussion: Whether plasma vs. serum is assayed can have a large impact on the observed concentration of some proteins, including several proteins that are of great interest to AD pathophysiology. The current findings may explain the significant discrepancies often times reported in the AD biomarker field.